Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

December 31, 2011

Conditions
Breast Cancer Metastatic
Interventions
DRUG

Irinotecan plus capecitabine

"Irinotecan 80 mg/m2 intravenously for 90 minutes once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period.~Capecitabine is administered orally at a dose of 1,000 mg/m2 twice daily (total daily dose 2,000 mg/m2) as an intermittent regimen in 3-week cycles (2 weeks of treatment followed by a 1-week rest period)."

Trial Locations (1)

410-769

National Cancer Center, 809 Madu1-dong, Ilsandong-gu, Goyang-si

All Listed Sponsors
lead

National Cancer Center, Korea

OTHER_GOV

NCT00532714 - Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC | Biotech Hunter | Biotech Hunter